In her recent letter to the editor, Dr Alice C. Ceacareanu cited the underutilization of metformin in insulin-resistant patients diagnosed with cancer and pointed to the potential survival benefit they may receive. 1 One reason metformin may be underutilized is safety concerns related to chemotherapy regimens impairing renal function or drug-drug interactions reducing metformin's clearance (CL) and leading to toxicity, the primary concern being fatal lactic acidosis resulting from high metformin concentrations.
The physiochemical properties of metformin, low number of hydrogen bond acceptors, low molecular weight, low polar surface area, and a low partition coefficient make it a molecule that prefers aqueous environments and undergoes almost no passive diffusion across membranes. 2, 3 Additionally, metformin is cationic at physiologic pH and a substrate for cation transporters (CTs). Despite thorough CT expression in enterocytes, metformin's absorption from the gut is almost entirely passive via the paracellular route. This is only possible because of the highly perfused thin epithelium of the gut's vasculature. However, the consequence of this is highly variable bioavailability (F, mean ¼ 50%-60%, range ¼ 20%-75%). [4] [5] [6] Nonetheless, F's variability has not been reported to cause clinically significant events.
Once reaching the blood stream a substantial amount of metformin selectively accumulates in erythrocytes and wellperfused tissues that express CTs, including the liver, kidney, adrenal gland, and pancreatic a cells but not b cells. [7] [8] [9] [10] Since metformin does not bind to plasma proteins, a fact that reduces the likelihood of drug-drug interactions, and has a very large volume of distribution (Vd; 654 + 358 L), one can confirm that its accumulation is mostly extravascular. 6 Furthermore, most active transport by CTs is largely unidirectional into cytoplasm. This means metformin has a very long, slow washout period with concentrations measured in erythrocytes being indicative of plasma concentration peaks from the past 3 or more days as opposed to plasma concentrations that have a half-life of 6.2 hours. 6 In the liver, although hepatic CTs efficiently uptake metformin, it is neither a substrate for hepatic metabolism nor biliary excretion, a fact that further reduces the risk of drug-drug interactions. In the kidney, however, CTs play a major role in the CL of metformin, resulting in CL values reaching in excess of 600 mL/min but dipping as low as <200 mL/min in lowactivity variants and renally impaired subjects. 2, 11, 12 That being said, the variability has rather been attributed to the latter and directly correlated with creatinine clearance (CL cr ). 10, 11 In light of the link between CL cr and metformin CL, concern that renal impairment may result in plasma levels greater than the accepted safe threshold of 5 mg/mL may be justified. 6 However, during clinical trials involving insulin-resistant patients receiving 850 mg of metformin and having CL cr between 10 and 30 mL/min, the mean C max was only 3.93 with a standard deviation of 0.92. 6 Subsequent pharmacokinetic studies have demonstrated that even with a CL cr of 15 mL/min, 500 mg is likely a safe dose. 12 Both examples create a stark contrast to the suggestion that metformin is contraindicated in patients with CL cr <30 mL/min and, because CL from erythrocytes is slow, one could even monitor average metformin concentrations using erythrocytes, analogous to monitoring hemoglobin A1c instead of blood glucose, to assess risk of lactic acidosis.
Ultimately, it would then seem that the pharmacokinetic aspects of metformin favor the idea that it could very likely be safely administered under the current guidelines in patients with cancer by simply monitoring CL cr and, if an evidence for clinical benefit exists, one must then ask themself how can anyone wait longer before giving metformin to those patients with cancer who may benefit most, those already having insulin resistance?
